Key Highlights
- Novo Nordisk unveiled a multi-month subscription service for Wegovy, featuring 3-, 6-, and 12-month options for cash-paying customers
- Monthly costs for injections start at $329 (3-month plan) and drop to $249 (12-month plan), representing up to 29% savings versus the $349 standard price
- Wegovy pill subscriptions are priced between $289 and $249 monthly, compared to the regular $299 cost
- The subscription service is now accessible via telehealth platforms Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame launching shortly
- Eli Lilly commands approximately 60% of the branded U.S. GLP-1 market, while Novo captures roughly 39%
Novo Nordisk is launching a strategic offensive in the self-pay obesity medication sector with an innovative subscription framework for Wegovy, aiming to narrow the competitive divide with Eli Lilly in this rapidly evolving marketplace.
The Copenhagen-based pharmaceutical giant rolled out this initiative Tuesday, providing qualified self-paying customers the ability to secure consistent monthly pricing through three subscription tiers. Extended commitments deliver greater savings.
For Wegovy injections, customers pay $329 monthly with a 3-month commitment, $299 with a 6-month plan, and $249 with a 12-month subscription. These rates represent savings of up to 29% compared to the baseline $349 monthly cost.
The Wegovy pill formulation, which debuted in the United States this January, mirrors this pricing architecture: $289, $269, or $249 monthly, versus the standard $299 rate. The 12-month pill subscription can save patients up to $600 annually, while the injection plan offers savings of up to $1,200 yearly.
Monthly costs remain unchanged regardless of dosage adjustments, eliminating a significant source of pricing uncertainty for self-pay GLP-1 users.
The subscription service went live immediately on Ro, WeightWatchers, and LifeMD platforms. Integration with Hims & Hers, Sesame, and additional partners is anticipated shortly. Availability through Novo’s proprietary NovoCare pharmacy hasn’t been announced, though the company indicated potential future expansion.
Strategic Timing Behind the Launch
This rollout comes at a critical juncture. Novo faces mounting competitive challenges. Eli Lilly dominates approximately 60% of the U.S. branded GLP-1 marketplace, leaving Novo with roughly 39%. Lilly established its direct-to-consumer presence ahead of Novo, and its Zepbound medication has demonstrated stronger prescription momentum than Wegovy.
Novo has implemented significant organizational changes in response—replacing its chief executive, reducing headcount, and appointing new leadership for its American operations. This subscription program represents another component of that strategic repositioning.
The Wegovy pill formulation has attracted patients previously reluctant to use GLP-1 injections, making the pre-competition window particularly valuable. Lilly’s oral obesity medication is currently undergoing FDA evaluation, with potential approval anticipated in April.
Industry observers have noted Novo’s vulnerability in potential pricing competition, particularly after slashing the Wegovy injection’s standard self-pay cost from $499 to $349 last November—a substantial 30% reduction.
Competitive Landscape: Lilly’s Pricing Structure
Lilly’s Zepbound self-pay pricing begins at $299 monthly for the 2.5mg dosage, escalates to $399 for 5mg, and reaches $449 for higher doses through its “Self Pay Journey Program.”
The subscription model addresses a persistent industry challenge: treatment continuity. Research published in 2025 indicated that approximately 65% of obesity patients discontinue GLP-1 therapy within twelve months, frequently citing cost unpredictability and adverse reactions.
Ed Cinca, Novo’s head of marketing and patient solutions, emphasized that subscribers maintain the flexibility to cancel their subscription whenever desired during the active period.
The 4mg Wegovy pill dose, currently available at $149 monthly, will increase to $199 beginning in September. The recently authorized 7.2mg dosage will be incorporated into subscription offerings at a future date.
